Compare ReproCELL, Inc. with Similar Stocks
Dashboard
1
Poor Management Efficiency with a low ROE of 0.31%
- The company has been able to generate a Return on Equity (avg) of 0.31% signifying low profitability per unit of shareholders funds
2
With a fall in Net Sales of -15.05%, the company declared Very Negative results in Dec 25
3
Risky -
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
JPY 16,211 Million (Small Cap)
160.00
NA
0.00%
-0.66
-3.21%
1.87
Revenue and Profits:
Net Sales:
636 Million
(Quarterly Results - Dec 2025)
Net Profit:
27 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.06%
0%
18.06%
6 Months
-3.17%
0%
-3.17%
1 Year
0%
0%
0.0%
2 Years
14.37%
0%
14.37%
3 Years
-27.09%
0%
-27.09%
4 Years
-10.29%
0%
-10.29%
5 Years
-53.44%
0%
-53.44%
ReproCELL, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.94%
EBIT Growth (5y)
13.17%
EBIT to Interest (avg)
-518.22
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.44
Sales to Capital Employed (avg)
0.32
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.31%
Valuation key factors
Factor
Value
P/E Ratio
160
Industry P/E
Price to Book Value
1.84
EV to EBIT
-96.27
EV to EBITDA
-157.51
EV to Capital Employed
2.49
EV to Sales
4.21
PEG Ratio
0.81
Dividend Yield
NA
ROCE (Latest)
-2.59%
ROE (Latest)
1.15%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY
Dec'25
Dec'24
Change(%)
Net Sales
635.70
748.40
-15.06%
Operating Profit (PBDIT) excl Other Income
-111.00
-17.00
-552.94%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
27.40
73.20
-62.57%
Operating Profit Margin (Excl OI)
-203.90%
-41.50%
-16.24%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2025 is -15.06% vs 18.87% in Dec 2024
Consolidated Net Profit
YoY Growth in quarter ended Dec 2025 is -62.57% vs 685.60% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
2,978.60
2,426.80
22.74%
Operating Profit (PBDIT) excl Other Income
-79.70
-372.20
78.59%
Interest
0.00
0.00
Exceptional Items
0.00
-63.70
100.00%
Consolidate Net Profit
103.20
-31.40
428.66%
Operating Profit Margin (Excl OI)
-43.80%
-168.70%
12.49%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 22.74% vs -17.83% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is 428.66% vs 89.72% in Mar 2024
About ReproCELL, Inc. 
ReproCELL, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






